• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Gamida Cell’s NiCord cell graft yields fewer infections, shorter hospital stays

April 21, 2017 By Sarah Faulkner

Gamida CellGamida Cell said today that its NiCord cell graft produces fewer infections, shorter hospital stays and shorter time to engraftment compared to standard umbilical cord blood transplantation.

The company’s work was published in Biology of Blood and Marrow Transplantation. 

“Our results indicate that rapid hematopoietic recovery from Gamida Cell’s NiCord transplantation approach is associated with clinical benefit. Reducing the burden of infections is important, as these are a major cause of early morbidity and death of patients following UCB transplantation,” principal investigator Dr. Mitchell Horwitz said in prepared remarks.

The treatment is a graft derived from umbilical cord blood which has been expanded and enriched with stem and progenitor cells. The Jerusalem-based company’s cell graft was designed as an alternative to bone marrow transplantation for patients with blood cancer who do not have a fully matched donor.

“NiCord continues to demonstrate significant advantages over standard UCB transplantation in clinical efficacy and in pharmaco-economic parameters enhancing our understanding of the market potential of the product,” president & CEO Yael Margolin added. “Our Phase III registration trial of NiCord is ongoing in which we hope to reproduce these important results in a larger patient population.”

The study compared 18 patients transplanted with NiCord and 86 patients treated with standard umbilical cord blood transplantation.

Researchers reported that the median time to neutrophil engraftment in NiCord patients was 12.5 days compared to 27 days in standard umbilical cord blood patients. Frequency of infection was 22% for NiCord patients compared to 54% for UCB patients.

The team also noted that NiCord patients had nearly 22 more days out of the hospital in the 1st 100 days compared to standard UCB patients.

Filed Under: Clinical Trials, Featured, Oncology, Stem Cells Tagged With: Gamida Cell

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS